Welcome!‎ > ‎


    McNeel DG. TCR diversity - a universal cancer immunotherapy biomarker? J Immunother Cancer. 2016 Nov 15;4:69. PMID: 27879971

    Colluru VT, Zahm CD, McNeel DG. Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses. Oncoimmunology. 2016 Sep 2;5(10):e1223002. PMID: 27853647

    Colluru VT, McNeel DG. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines. Oncotarget. 2016 Sep 21. doi: 10.18632/oncotarget.12178. PMID: 27661128 

    Rekoske BT, McNeel DG. Immunotherapy for prostate cancer: False promises or true hope? Cancer. 2016 Dec 1;122(23):3598-3607. doi: 10.1002/cncr.30250. PMID: 27649312

    Rekoske BT, Olson BM, McNeel DG. Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology. 2016 Mar 28;5(6):e1165377. doi: 10.1080/2162402X.2016.1165377. PMID: 27471641

    Bloom JE, McNeel DG. SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. Oncotarget. 2016 Jun 2. doi: 10.18632/oncotarget.9802. PMID: 27276714

    Colluru VT, Johnson LE, Olson BM, McNeel DG. Preclinical and clinical development of DNA vaccines for prostate cancer. Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Review. PMID: 24332642

    Bradley ES and McNeel DG. “DNA Vaccines.” Marshall JL ed. Encyclopedia of Cancer Therapeutic Targets. New York: Springer, 2016.

    McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS. Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). Hum Vaccin Immunother 2015;11(10):2469-74. doi: 10.1080/21645515. 2015.1062190. PMID: 26111351

    Rekoske BT, Smith HA, Olson BM, Maricque BB, McNeel DGPD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res. 2015 Aug;3(8):946-55. doi: 10.1158/2326-6066.CIR-14-0206. Epub 2015 Jun 3. PMID: 26041735

        McNeel DG, Becker JT, Eickhoff JC, Johnson LE, Bradley E, Pohlkamp I, Staab MJ, Liu G, Wilding G, Olson BM.  Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.  Clin Cancer Res.  2014 Jul 15;20(14):3692-704. doi: 10.1158/1078-0432.

        Smith HA, Rekoske BT, McNeel DG. DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses. Vaccine. 2014 Mar 26;32(15):1707-15. doi: 10.1016/j.vaccine.2014.01.048. 

        Olson BM, McNeel DG. Monitoring regulatory immune responses in tumor immunotherapy clinical trials. Front Oncol. 2013 May 6;3:109. doi: 10.3389/fonc.2013.00109.

        Lang JM, Wallace M, Becker JT, Eickhoff JC, Buehring B, Binkley N, Staab MJ, Wilding G, Liu G, Malkovsky M, McNeel DG.  A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.Clin Genitourin Cancer. 2013 Dec;11(4):407-15. doi: 10.1016/j.clgc.2013.04.029. 

         Johnson LE, Becker JT, Dubovsky JA, Olson BM, McNeel DGProstate carcinoma in transgenic Lewis rats - a tumor model for evaluation of immunological treatments. Chin Clin Oncol. 2013 Mar 1;2(1). doi: 10.3978/j.issn.2304-3865.2012.11.06.

        Becker JT, McNeel DG. Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.  J Immunother Cancer. 2013 May 29;1:2. doi: 10.1186/2051-1426-1-2.

        Casavant BP, Mosher R, Warrick JW, Maccoux LJ, Berry SM, Becker JT, Chen V, Lang JM, McNeel DG, Beebe DJ.  A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells.  Methods. 2013 Dec 1;64(2):137-43. doi: 10.1016/j.ymeth.2013.05.027.

        Olson BM, Jankowska-Gan E, Becker JT, Vignali DA, Burlingham WJ, McNeel DG.Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol. 2012 Dec 15;189(12):5590-601. doi: 10.4049/jimmunol.1201744  

        Bloom JE, McNeel DG, and Olson BM.  Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.Expert Rev Vaccines. 2012 Dec;11(12):1401-4. doi: 10.1586/erv.12.122.

        Johnson LE, Frye TP, McNeel DGImmunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response. Oncoimmunology. 2012 Dec 1;1(9):1546-1556.     

       Olson BM and McNeel DG.  Antigen loss and tumor-mediated immunosuppression facilitate tumor recurrence.  Expert Rev Vaccines. 2012 Nov;11(11):1315-7. doi: 10.1586/erv.12.107.

       McNeel DG, Becker JT, Johnson LE, and Olson BM.  DNA Vaccines for Prostate Cancer.Curr Cancer Ther Rev. 2012 Nov 1;8(4):254-263.
        Bruce JY, Lang JM, McNeel DG, Liu G.  Current controversies in the management of biochemical failure in prostate cancer.  Clin Adv Hematol Oncol. 2012 Nov;10(11):716-22.

        Smith HA and McNeel DG. (2010) “The SSX family of cancer-testis antigens as target proteins for tumor therapy.” Clin. Dev. Immunol. 2010:150591.

        Alam S and McNeel DG. (2010) “DNA vaccines for the treatment of prostate cancer.” Exp. Rev. Vaccines 9:731-745.

        Gao JJ, Maricque BB, Morse MD, Huang W, and McNeel DG. (2010) “Identification of autoantibodies in a patient with testicular cancer and concurrent inflammatory bowel disease.” J. Clin. Oncol. 28:e680-683.

        Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, and McNeel DG. (2010) “DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.” J Immunotherapy 33:639-647.

        Morse MD and McNeel DG. (2010) “Prostate cancer patients treated with androgen deprivation therapy develop persistent changes in adaptive immune responses.” Human Immunology 71:496-504.


1.      Comments on McNeel DG (2009) J. Clin. Oncol. 27:4047-4054

a.       Drake CG.  (2009)  “Immunotherapy for prostate cancer:  walk, don’t run.”  J. Clin. Oncol. 27:4035-4037

b.      Smith MR and Kantoff PW.  (2010)  “Changes in PSA kinetics after DNA vaccine therapy – not so fast!”  J. Clin. Oncol. 28:e58

        Ward J and McNeel DG. (2007) “GVAX: An allogeneic, whole-cell, GM-CSF-secreting vaccine for the treatment of prostate cancer.” Exp. Opin. Biol. Ther. 7:1893-1902.

        Kipp RT and McNeel DG. (2007) “Immunotherapy of prostate cancer.” Clin. Adv. Hem. Onc. 5:465-479.

        McNeel DG. (2007) “Prostate cancer immunotherapy.” Curr. Opin. Urol. 17:175-181.

        McNeel DG. (2007) “Cellular immunotherapies for prostate cancer.” Biomed Pharmacother. 61:315-322.

        Dubovsky JA and McNeel DG. (2007) “Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.” Prostate 67:1781-1790.

        Olson BM and McNeel DG. (2007) “Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.” Prostate 67:1729-1739.

        Dubovsky JA, Albertini MR and McNeel DG. (2007) “MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.” J. Immunotherapy 30:675-683.

        Johnson LE, Frye TP, Chinnasamy D, Chinnasamy N, and McNeel DG. (2007) “Plasmid DNA vaccine encoding prostatic acid phosphatase (PAP) effective in eliciting autologous antigen-specific CD8 T cells.” Cancer Immunol Immunother 56:885-895.
        Dunphy EJ, Johnson LE, Olson BM, Frye TP, and McNeel DG. (2006) “New approaches to identification of antigenic candidates for future prostate cancer immunotherapy.” Update on Cancer Therapeutics 22:273-284.

        Hoeppner LH, Dubovsky JA, Dunphy EJ, and McNeel DG. (2006) “Humoral immune responses to testis antigens in sera from patients with prostate cancer.” Cancer Immun. [serial online] 6:1-7.

        Mooney CJ, Dunphy EJ, Stone B, and McNeel DG. (2006) “Prostate cancer presenting as dermatomyositis: Case report and immunological analysis.” Int. J. Urol. 13:211-217.

        Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, and McNeel DG. (2006) “Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).” Vaccine 24:293-303.

        McNeel DG and Malkovsky M. (2005) “Immune-based therapies for prostate cancer.” Immunol. Lett. 96:3-9.

        McNeel DG. “Prostate cancer antigens and vaccines, preclinical developments.” In: Giaccone G, Schilsky R, Sondel P. eds. Cancer Chemotherapy and Biological Response Modifiers, Annual 22. Oxford: Elsevier Limited, 2005 p. 247-261.

        Dunphy EJ and McNeel DG. (2005) “Antigen-specific IgG elicited in subjects with prostate cancer treated with flt3 ligand.” J. Immunotherapy 28:268-275.

        Dunphy EJ, Eickhoff JC, Muller CH, Berger RE, and McNeel DG. (2004) “Identification of antigen-specific IgG in sera from patients with chronic prostatitis.” J. Clin. Immunol. 24:492-502.